This article is more than 5 years old. Information may no longer be current.

Intralesional triamcinolone effective in chalazion treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Injection of triamcinolone acetonide into primary or recurrent chalazia results in regression in most cases, according to a retrospective study. Eighty percent of cases in that study resolved with one or two injections. Lesions that do not regress are “more likely to benefit from surgical excision,” the study authors said.

Guy J. Ben Simon, MD, and colleagues reviewed the records of 147 patients with primary or recurrent chalazia who were treated at the Jules Stein Eye Institute in Los Angeles from January 2000 to December 2003. Patients received intralesional injections of 0.1 to 0.2 mL of triamcinolone acetonide. Success was defined as a decrease of at least 80% in lesion size with no recurrence.

Patients who did not respond to two injections were more likely to fail treatment, to respond to further injections or to undergo surgical excision and drainage. IOP and visual acuity remained stable after treatment. No complications were noted.

The study is published in the May issue of Ophthalmology.